Patents Assigned to Genentech
  • Publication number: 20110097325
    Abstract: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.
    Type: Application
    Filed: May 7, 2009
    Publication date: April 28, 2011
    Applicant: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Iqbal Grewal, Austin L. Gurney
  • Publication number: 20110097330
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes.
    Type: Application
    Filed: February 27, 2006
    Publication date: April 28, 2011
    Applicants: Genentech, Inc., Lexicon Pharmaceuticals, Inc.
    Inventors: Allison Anne Byers Horner, Catherine Batac Clarke, Katherin E. Combs, Frederic J. de Sauvage, Joel Edwards, Paul Godowski, Deanna Grant Wilson, Wenhu Huang, Lorelei Diane Ketcherside, Erin Marie Massey, Charles Montgomery, Bobby Joe Payne, Andrew Peterson, Ni Nancy Qian, Jeffrey J. Schrick, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Colleen M. Viator, Peter Vogel, Weilan Ye, Jung-Hua Yeh, Zhiyong Ding
  • Publication number: 20110098449
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Application
    Filed: September 15, 2010
    Publication date: April 28, 2011
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • Patent number: 7931902
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: April 26, 2011
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Gretchen Frantz, Charles Montgomery, Franklin Peale, Zheng-Zheng Shi, Mary Jean Sparks
  • Patent number: 7932026
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: April 26, 2011
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Publication number: 20110092479
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 21, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jason De Meese, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, David Moreno, Brad Newhouse, Li Ren, Jeongbeob Seo, Hongqi Tian, Steven M. Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • Publication number: 20110091477
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Application
    Filed: October 18, 2010
    Publication date: April 21, 2011
    Applicant: Genentech, Inc.
    Inventors: Rajkumar Ganesan, Daniel Kirchhofer
  • Patent number: 7927592
    Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv,b small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 19, 2011
    Assignee: Genentech, Inc.
    Inventor: Michael S C Fung
  • Patent number: 7930109
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Patent number: 7928248
    Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: April 19, 2011
    Assignees: Genentech, Inc., Hoffman-La Roche Inc.
    Inventors: Steven Do, Richard Goldsmith, Tim Heffron, Aleksandr Kolesnikov, Steven Staben, Alan G. Olivero, Michael Siu, Daniel P. Sutherlin, Bing-Yan Zhu, Paul Goldsmith, Tracy Bayliss, Adrian Folkes, Neil Pegg
  • Publication number: 20110086841
    Abstract: The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.
    Type: Application
    Filed: November 10, 2010
    Publication date: April 14, 2011
    Applicant: Genentech, Inc.
    Inventors: Zhonghua Pei, Joseph P. Lyssikatos, Kevin Hon Luen Lau, Wendy Lee, Kirk D. Robarge
  • Publication number: 20110086837
    Abstract: The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein.
    Type: Application
    Filed: October 11, 2010
    Publication date: April 14, 2011
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Iris T. Chan, Lori Friedman, Klaus P. Hoeflich, John Prescott, Jeffrey Wallin
  • Publication number: 20110086032
    Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
    Type: Application
    Filed: October 27, 2010
    Publication date: April 14, 2011
    Applicant: GENENTECH, INC.
    Inventors: LUC DESNOYERS, DOROTHY FRENCH
  • Publication number: 20110086840
    Abstract: The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.
    Type: Application
    Filed: November 10, 2010
    Publication date: April 14, 2011
    Applicant: Genentech, Inc.
    Inventors: Zhonghua Pei, Joseph P. Lyssikatos, Wendy Lee, Kirk D. Robarge
  • Patent number: 7923011
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: April 12, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Patent number: 7923456
    Abstract: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 12, 2011
    Assignee: Genentech, Inc.
    Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
  • Patent number: 7923221
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: April 12, 2011
    Assignees: Genentech, Inc, City of Hope
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Publication number: 20110081342
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: December 7, 2010
    Publication date: April 7, 2011
    Applicant: GENENTECH, INC.
    Inventors: MANUEL BACA, JAMES A. WELLS, LEONARD G. PRESTA, HENRY B. LOWMAN, YVONNE MAN-YEE CHEN
  • Patent number: 7919254
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: April 5, 2011
    Assignee: Genentech, Inc.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Publication number: 20110076273
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 31, 2011
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch